Education and Training
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: AMG 655
- other: Placebo
- drug: Doxorubicin
Eligibility
Inclusion Criteria:
- Histologically or cytologically confirmed soft tissue sarcoma
- Locally advanced, recurrent, or metastatic, unresectable disease
- Measurable disease according to modified RECIST
- ECOG performance status of 0 or 1
- Men or women at least 18 years of age
- Adequate hematological, renal, hepatic, and coagulation function
Exclusion Criteria:
- Prior treatment with anthracyclines
- Uncontrolled cardiovascular disease
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Ahern
6507256413
Not Recruiting